Given the worldwide epidemic and the speedy evolution of COVID-19, several pharmaceutical and biotechnology companies are trying to find efficient solutions to treat and prevent the disease. Several studies are being conducted to develop vaccines against the virus. In a similar attempt, one of the biotechnology companies has successfully discovered a new avenue of therapy against the virus. A US-based biotechnology company has recently identified two monoclonal antibodies that can bind to the COVID-19 and neutralize its activity.
These antibodies were obtained from an existing library of 20 fully-human antibodies. The company claims that the antibodies act on the SARS-CoV-2 spike protein present in the region used by the virus to enter cells via cellular receptor ACE2. If found safe and effective, the antibodies can not only offer treatment but can also confer prophylaxis. The discovery…
